Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : in talks with FDA to expand COVID-19 vaccine pediatric study

07/26/2021 | 01:56pm EDT

July 26 (Reuters) - Moderna Inc is in talks with U.S. regulators to expand the size of an ongoing trial testing its COVID-19 vaccines in children aged between five and 11, the drugmaker said on Monday.

The objective of the discussion with the U.S. Food and Drug Administration is to enroll a larger safety database, which increases the likelihood of detecting rarer events, the company said.

Moderna expects to have a package that supports authorization in winter of 2021 or early 2022, a company spokesperson told Reuters.

Earlier in the day, the New York Times reported the U.S. regulators have asked Pfizer Inc-BioNTech and Moderna to expand the size of the trial.

They claimed the strength of the studies was inadequate to detect the rare side effects, including myocarditis, an inflammation of the heart muscle and pericarditis, an inflammation of the lining around the heart, the report said.(https://nyti.ms/3xgzuWZ)

Pfizer said it has not provided any updates to its previously stated timelines. It had previously said it expects to have data for children aged between 5 and 11 in September.

The health regulator has asked the companies to include 3,000 children in their trials, almost double the original number of study participants, the NYT report said, citing people familiar with the matter.

FDA did not immediately respond to Reuters request for comment. (Reporting by Mrinalika Roy in Benagluru and Michael Erman in New Jersey; Editing by Shinjini Ganguli)


ę Reuters 2021
All news about MODERNA, INC.
05:16pMODERNA : U.S. administers 387.5 mln doses of COVID-19 vaccines - CDC
RE
05:09pMODERNA : U.S. CDC Says 182,387,840 Individuals Have Been Fully Vaccinated Against Covid-1..
RE
04:23pMODERNA : Canada paused COVID-19 vaccine deliveries as supply far exceeds demand
AQ
02:58pMODERNA : COVID SCIENCE-Severe COVID-19 may trigger autoimmune conditions; New variants ca..
RE
02:48pMODERNA : U.S. CDC advisers could vote on Pfizer COVID-19 vaccine booster on Thursday
RE
08:29aWHITE HOUSE REPORTEDLY URGED PFIZER : NY Times
MT
06:40aTHE LATEST : Michigan passes 1 million coronavirus cases
AQ
12:17aIndia Unlikely to Order Pfizer, Moderna COVID-19 Jabs As Local Vaccine Output Soars
MT
09/21MODERNA : Brazil and Argentina tapped to make mRNA vaccines in Latin America
RE
09/21MODERNA : U.S. administers 386.8 mln doses of COVID-19 vaccines - CDC
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 348 M - -
Net income 2021 12 529 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 14,8x
Yield 2021 -
Capitalization 178 B 178 B -
EV / Sales 2021 8,11x
EV / Sales 2022 7,50x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 440,72 $
Average target price 306,23 $
Spread / Average Target -30,5%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.321.86%175 199
LONZA GROUP AG33.16%60 866
IQVIA HOLDINGS INC.43.03%49 103
CELLTRION, INC.-23.26%31 708
SEAGEN INC.-5.78%30 021
PHARMARON BEIJING CO., LTD.81.89%25 723